Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin in Very Preterm Infants

This study reports 5-year neurodevelopmental outcomes for Swiss children born before 32 weeks ’ gestation and randomized at birth to receive early high-dose recombinant human erythropoietin (rhEpo) vs placebo.
Source: JAMA - Category: General Medicine Source Type: research